Insights Archive
Filter by:
January 11, 2024
Navigating 2024: Three topics shaping the pharmacy benefit
As we reflect on the developments of 2023 and set our sights on 2024, the pharmacy benefit landscape is undergoing significant transformations. Read on to learn what ClearScript is watching in this evolving and complex field to stay ahead of changes that will impact the pharmacy benefit.
January 11, 2024
New Drug Spotlight: Zepbound
On November 8, 2023, Eli Lilly announced the approval of the newest weight loss drug Zepbound, a much-anticipated formulation of tirzepatide in the high-profile GLP-1 agonist medications class. Used along with reduced calorie diet and exercise, studies have shown Zepbound can lead to significant weight loss.
October 30, 2023
Losing money or losing weight? How the new GLP-1 drugs are affecting your benefit plan
ClearScript’s Vice President of Clinical Operations, Yalda Olcott, PharmD, presents an educational look at how GLP-1 drugs are driving plan spend including their indications, benefits, industry insight, and strategies for navigating these drugs in your benefit plan.
October 2, 2023
New Drug Spotlight: Arexvy, Abrysvo, and Beyfortus
In 2023, the U.S. Food & Drug Administration (FDA) approved three new vaccines for the prevention of Respiratory Syncytial Virus (RSV). RSV is a highly contagious, common respiratory virus that typically causes mild cold-like symptoms. However, it can cause serious illness in older adults and infants.
September 29, 2023
Insulin Update
Amidst growing public and government attention on insulin affordability, what do plan sponsors need to know as they plan coverage strategies in 2024 and beyond?
May 30, 2023
Weight loss drugs and pharmacy benefit coverage
As more people are lured to these medications with hopes of an effective weight loss solution, many plan sponsors are growing concerned about their impact on plan spend.
May 30, 2023
New Drug Spotlight: Amjevita
The launch of Amjevita, the first FDA-approved biosimilar for Humira, is big news for pharmacy benefit plan sponsors.
May 30, 2023
First in a new class
An estimated 8 million adults in the U.S. have psoriasis. Last month, the FDA approved Sotyktu (deucravacitinib), the first in a new class of oral medication to treat plaque psoriasis. Will this new product be revolutionary or evolutionary when it comes to plaque psoriasis therapy?
May 30, 2023
Are you watching this?
Alzheimer’s drug pipeline news: Biogen Inc. in partnership with Eisai Co. has released encouraging data about their new anti-amyloid monoclonal antibody therapy (lecanemab) currently in clinical trials.